Innovative Medical Solutions Provider Enters the Biologics Wound Care Market with Acquisition of Leader in Lyophilized Amniotic Membrane Technology
Dakota Dunes, SD, and Las Vegas, NV, March 19, 2025 – New Horizon, an innovative provider of medical solutions and practice optimization services, today announced that it has closed on the acquisition of Precise Bioscience, a leader in advanced lyophilized amniotic membrane technology-based products. Terms of the transaction were not disclosed stemming from the acquisition on December 29, 2024.
Founded in 2019 and based in Las Vegas, NV, New Horizon has established itself as a leading provider in the biologics wound care market through its novel approach, process, and product offerings. The company focuses on delivering practice optimization services, full-practice billing, and now best-in-class biologics products designed to enhance patient outcomes while reducing the total cost of care.
“This acquisition fulfills the roadmap we envisioned when we founded New Horizon,” said Will Hall, Founder and CEO. “We are thrilled to partner with a leader like Precise Bioscience, whose innovative technology enhances our ability to deliver superior patient care. Together, we will empower healthcare providers with products that accelerate healing, reduce complications, and improve the patient experience.”
The Precise Bioscience product portfolio includes the Xcell Amnio Matrix (XAM) family and Xcellerate, advanced lyophilized amniotic membrane products designed for flexibility and ease of use. Featuring a proprietary process that preserves the extracellular matrix and growth factors, these products serve as natural biologic barriers supporting re-epithelialization, making them ideal for chronic wounds, pressure ulcers, surgical sites, and reconstructive applications.
Commitment to Patient-Centric Innovation
With this acquisition, New Horizon strengthens its commitment to advancing patient-centric care by:
- Expanding access to clinically proven biologics that promote faster healing and reduce the need for costly interventions.
- Providing healthcare providers with easy-to-use grafts that adapt to a variety of patient needs, minimizing time in the procedure and improving patient comfort.
- Supporting value-based care models by offering products that contribute to better healing rates and fewer complications, ultimately reducing hospital readmissions.
- Continuing investment in clinical research and education to help healthcare providers stay at the forefront of regenerative medicine and wound care best practices.
“The acquisition by New Horizon validates the strength of the product portfolio we built from day one,” said Nate Schipper, founder of Precise Bioscience. “We couldn’t ask for a better partner to advance these products and deliver measurable impact for patients and providers alike.”
About New Horizon
New Horizon Medical Solutions is a fast-growing biologics company providing advanced products and services designed to optimize patient care and enhance healthcare practice performance. Headquartered in Las Vegas, NV, New Horizon is a recognized leader in the global wound care market and remains committed to improving outcomes, driving efficiency, and elevating the standard of care.
For more information, visit www.nhmedical.com
Media Contact:
New Horizon
ir@nhmedical.com
702.960.2913